Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Consensus Target Price from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $17.25.

ENTA has been the subject of several recent analyst reports. Robert W. Baird cut their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. HC Wainwright cut their price objective on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, December 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th.

Insiders Place Their Bets

In related news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Krensavage Asset Management LLC lifted its stake in shares of Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after purchasing an additional 246,736 shares during the period. Erste Asset Management GmbH purchased a new position in Enanta Pharmaceuticals in the third quarter valued at about $1,243,000. Point72 Asset Management L.P. acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter valued at approximately $903,000. JPMorgan Chase & Co. boosted its stake in shares of Enanta Pharmaceuticals by 53.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after acquiring an additional 85,082 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Enanta Pharmaceuticals by 34.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock worth $1,109,000 after acquiring an additional 49,050 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Trading Down 0.2 %

NASDAQ:ENTA opened at $5.53 on Monday. The company has a market cap of $117.20 million, a P/E ratio of -1.01 and a beta of 0.56. Enanta Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $17.80. The company’s 50-day moving average price is $6.73 and its 200-day moving average price is $10.46.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same period last year, the firm posted ($1.33) EPS. The business’s quarterly revenue was down 22.8% on a year-over-year basis. On average, analysts expect that Enanta Pharmaceuticals will post -4.93 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.